Cohance Lifesciences Shares In Focus As Jefferies Initiates Coverage With 'Buy' Rating: Check Target Price
Published on: Aug. 25, 2025, 7:52 a.m. | Source: NDTV Profit
Jefferies has initiated coverage on Cohance Lifescience with a 'Buy' rating and a price target of Rs 1,150, citing the company's differentiated technology-led CRDMO platofrm and strong positioning in the fast-growing Antibody Drug Conjugate segment.
